We’re developing a pipeline of innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Our lead program, REN-001, is being developed for BAG3-associated dilated cardiomyopathy (DCM) and uses gene transfer technology to address the monogenic cause of this severe form of heart failure.